Ivermectin to reduce malaria transmission II. Considerations
                regarding clinical development pathway

All of RECERCAT

To access the full text documents, please follow this link: http://hdl.handle.net/2445/110769

dc.contributor.author	Chaccour, Carlos
dc.contributor.author	Rabinovich, Regina
dc.date	2017-05-10T13:26:31Z
dc.date	2017-05-10T13:26:31Z
dc.date	2017-04-24
dc.date	2017-05-03T18:01:50Z
dc.identifier.citation	1475-2875
dc.identifier.uri	http://hdl.handle.net/2445/110769
dc.description.abstract	The development of ivermectin as a complementary vector control tool will require good quality evidence. This paper reviews the different eco-epidemiological contexts in which mass drug administration with ivermectin could be useful. Potential scenarios and pharmacological strategies are compared in order to help guide trial design. The rationale for a particular timing of an ivermectin-based tool and some potentially useful outcome measures are suggested.
dc.format	13 p.
dc.format	application/pdf
dc.language.iso	eng
dc.publisher	Biomed Central
dc.relation	Reproducció del document publicat a: http://dx.doi.org/10.1186/s12936-017-1802-3
dc.relation	Malaria Journal, 2017, vol. 16, num. 1, p. 166
dc.relation	http://dx.doi.org/10.1186/s12936-017-1802-3
dc.rights	cc by (c) Chaccour et al., 2017
dc.rights	info:eu-repo/semantics/openAccess
dc.rights	http://creativecommons.org/licenses/by/3.0/es/
dc.subject	Malària
dc.subject	Assaigs clínics
dc.subject	Malaria
dc.subject	Clinical trials
dc.title	Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion